Related Experiment Videos

Kinetics of urinary furosemide elimination in infants

Developmental Pharmacology and Therapeutics
|January 1, 1984
PubMed

Insights

Furosemide (F) elimination in infants shows similar urinary excretion to adults. However, infants with pneumonia and cardiac insufficiency exhibit slower F elimination, indicating potential dosage adjustments are needed.

Area of Science:

  • Pharmacokinetics
  • Pediatric Pharmacology
  • Nephrology

Background:

  • Furosemide is a diuretic commonly used in infants.
  • Understanding furosemide's elimination kinetics is crucial for safe and effective dosing in pediatric populations.
  • Renal function immaturity in infants may affect drug metabolism and excretion.

Purpose of the Study:

  • To investigate the urinary elimination kinetics of furosemide in infants.
  • To determine the elimination half-life (t1/2) of furosemide in infants using a noninvasive method.
  • To compare furosemide elimination in infants with and without pneumonia and cardiac insufficiency.

Main Methods:

  • A one-compartment model was used to study furosemide elimination.
  • A single intravenous dose of 1 mg/kg furosemide was administered to 13 infants (9 days to 12 months) and one 23-month-old child.
  • Urinary excretion data was used to determine the drug's elimination half-life noninvasively.

Main Results:

  • Furosemide elimination half-life in infants ranged from 0.654 to 3.29 hours.
  • Cumulative urinary excretion of furosemide in infants was comparable to healthy adults.
  • Infants with pneumonia and cardiac insufficiency had a significantly longer mean furosemide elimination half-life (2.15 h) compared to those with pneumonia alone (1.01 h).

Conclusions:

  • Renal function immaturity in the first year of life does not appear to significantly impact the elimination kinetics of a 1 mg/kg intravenous furosemide dose in infants.
  • Slower furosemide elimination in infants with pneumonia and cardiac insufficiency suggests a need for careful dosage consideration in these patients.
  • Further research may be warranted to explore the impact of specific disease states on furosemide pharmacokinetics in infants.

Related Concept Videos